Sosei Group Corporation will acquire from Idorsia all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd. The strategic transaction also includes the Japan and APAC (ex-China) territory rights to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ already commercially available and with fast-growing sales in Japan following a successful launch in April 2022.
MORE
